Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Disrupting Mitohormesis As a Novel Therapeutic Strategy for Multiple Myeloma (MM) Including Those with High Risk Disease and Proteosome Inhibitor Resistance

Serges P Tsofack, Danielle C Croucher, Benjamin G Barwick, Zhihua Li, Ahmed Aman, Dennis Tao, Ellen nong Wei, Laura Garcia Prat, Aaron D Schimmer, Suzanne Trudel

Blood (2021) 138 (Supplement 1): 722.

https://doi.org/10.1182/blood-2021-148673

Published: 2021

Journal Articles

Selective Cell State in the Clonally Expanded T-Cell Compartment of Vκ*MYC Mice Responding to Treatment with Checkpoint Inhibitors

Danielle C Croucher, Laura M Richards, Zhihua Li, Ellen nong Wei, Xian Fang Huang, Daniel Waller, Marta Chesi, P. Leif Bergsagel, Michael Sebag, Trevor J. Pugh, Suzanne Trudel

Blood (2021) 138 (Supplement 1): 1581.

https://doi.org/10.1182/blood-2021-151242

Published: 2021

Journal Articles

A Single-Cell Transcriptional Analysis of Tumour Cells and the Immune Microenvironment during Disease Evolution in a Transgenic Mouse Model of Myeloma

Danielle C Croucher, MSc, Marta Chesi, PhD, Zhihua Li, Victoria Marie Garbitt, BS, Meaghen E Sharik, BS, Daniel Waller, PhD, Michael Sebag, MD PhD, P. Leif Bergsagel, MD, Trevor J. Pugh, PhD, Suzanne Trudel, MD FRCP(C)

Blood (2018) 132 (Supplement 1): 56.

https://doi.org/10.1182/blood-2018-99-118691

Published: 2018

Journal Articles

A Novel Small Molecule STAT Inhibitor, BP-4-018, Demonstrates Significant Anti-Tumour Activity and Synergism With Bortezomib In Pre-Clinical In Vivo Models Of Multiple Myeloma

Danielle C Croucher, MSc, BSc, Zhihua Li, Brent D.G. Page, PhD, Ellen Nong Wei, Patrick T. Gunning, PhD, Suzanne Trudel, MD, MSC, FRCPC

Blood (2013) 122 (21): 4441.

https://doi.org/10.1182/blood.V122.21.4441.4441

Published: 2013

Journal Articles

The Potent STAT3/5 Inhibitor, BP-1-102 Demonstrates Significant Anti-Tumor Activity Against Waldenström Macroglobulinemia

Danielle C Croucher, Victor H Jimenez-Zepeda, MD, PD, Zhi Hua Li, Ellen Wei, Brent DG Page, James Turkson, Patrick T Gunning, Suzanne Trudel, MD, MSC, FRCPC

Blood (2011) 118 (21): 5101.

https://doi.org/10.1182/blood.V118.21.5101.5101

Published: 2011

NARROW

Disrupting Mitohormesis As a Novel Therapeutic Strategy for Multiple Myeloma (MM) Including Those with High Risk Disease and Proteosome Inhibitor Resistance

Selective Cell State in the Clonally Expanded T-Cell Compartment of Vκ*MYC Mice Responding to Treatment with Checkpoint Inhibitors

A Single-Cell Transcriptional Analysis of Tumour Cells and the Immune Microenvironment during Disease Evolution in a Transgenic Mouse Model of Myeloma

A Novel Small Molecule STAT Inhibitor, BP-4-018, Demonstrates Significant Anti-Tumour Activity and Synergism With Bortezomib In Pre-Clinical In Vivo Models Of Multiple Myeloma

The Potent STAT3/5 Inhibitor, BP-1-102 Demonstrates Significant Anti-Tumor Activity Against Waldenström Macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Disrupting Mitohormesis As a Novel Therapeutic Strategy for Multiple Myeloma (MM) Including Those with High Risk Disease and Proteosome Inhibitor Resistance

Selective Cell State in the Clonally Expanded T-Cell Compartment of Vκ*MYC Mice Responding to Treatment with Checkpoint Inhibitors

A Single-Cell Transcriptional Analysis of Tumour Cells and the Immune Microenvironment during Disease Evolution in a Transgenic Mouse Model of Myeloma

A Novel Small Molecule STAT Inhibitor, BP-4-018, Demonstrates Significant Anti-Tumour Activity and Synergism With Bortezomib In Pre-Clinical In Vivo Models Of Multiple Myeloma

The Potent STAT3/5 Inhibitor, BP-1-102 Demonstrates Significant Anti-Tumor Activity Against Waldenström Macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only